ADMA Biologics, Inc. (ADMA): Net Income
$146.93M
Year ended 2025-12-31
$168.96M
Trailing 12 months to 2026-06-30
| Period ended | Net Income | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $146.93M | -25.7% | 2026-02-25, From 2025-01-01 |
| 2024-12-31 | $197.67M | n/m | 2026-02-25, From 2024-01-01 |
| 2023-12-31 | -$28.24M | n/m | 2026-02-25, From 2023-01-01 |
| 2022-12-31 | -$65.90M | n/m | 2025-03-18, From 2022-01-01 |
| 2021-12-31 | -$71.65M | n/m | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | -$75.75M | n/m | 2022-03-24, From 2020-01-01 |
| 2019-12-31 | -$48.28M | n/m | 2021-03-25, From 2019-01-01 |
| 2018-12-31 | -$65.74M | n/m | 2020-03-13, From 2018-01-01 |
| 2017-12-31 | -$43.76M | n/m | 2019-03-13, From 2017-01-01 |
| 2016-12-31 | -$19.52M | n/m | 2018-03-29, From 2016-01-01 |
| 2015-12-31 | -$17.97M | n/m | 2017-02-24, From 2015-01-01 |
| 2014-12-31 | -$16.81M | n/m | 2016-03-23, From 2014-01-01 |
| 2013-12-31 | -$15.53M | n/m | 2015-03-09, From 2013-01-01 |
| 2012-12-31 | -$7.30M | n/m | 2014-03-28, From 2012-01-01 |
| 2011-12-31 | -$5.90M | n/a | 2013-03-06, From 2011-01-01 |
Net Income at similar companies
| Company | Year ended | Net Income | Change YoY |
|---|---|---|---|
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $146.93M | -25.7% |
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | -$66.42M | n/m |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$35.51M | n/m |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $204.83M | +129.7% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$77.67M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $48.89M | n/m |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $263.86M | n/m |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | -$59.50M | n/m |
| Vericel Corp (VCEL) | 2025-12-31 | $16.52M | +59.4% |
Compare ADMA, TARS, IMCR, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗